What is Sientra?
Founded in 2003 and headquartered in Goleta, California, Sientra is a medical aesthetics company focused on the development and commercialization of silicone gel breast implants for plastic surgeons. The company's product portfolio aims to provide advanced solutions within the reconstructive and aesthetic surgery markets. Sientra's strategic focus on innovation in implant technology positions it within a niche but significant segment of the healthcare industry, catering to both patient and surgeon needs for high-quality, reliable aesthetic and reconstructive devices.
How much funding has Sientra raised?
Sientra has raised a total of $597M across 9 funding rounds:
Series C
$65M
Stock Offering
$80.2M
Stock Offering
$66M
Debt
$20M
Stock Offering
$107.7M
Stock Offering
$108.1M
Debt
$60M
Debt
$5M
Series C (2012): $65M led by Clarus Ventures, OrbiMed, and Abingworth
Stock Issuance/Offering (2014): $80.2M, investors not publicly disclosed
Stock Issuance/Offering (2015): $66M, investors not publicly disclosed
Debt (2017): $20M backed by Silicon Valley Bank
Stock Issuance/Offering (2018): $107.7M, investors not publicly disclosed
Stock Issuance/Offering (2019): $108.1M, investors not publicly disclosed
Debt (2020): $60M supported by Deerfield Communications Inc
Debt (2020): $5M featuring PPP
Key Investors in Sientra
OrbiMed
OrbiMed Advisors LLC operates as a specialized investment firm focused on the healthcare sector, with deep expertise spanning multiple therapeutic and commercial domains. The firm manages capital across biopharmaceuticals, medical devices, digital health platforms, diagnostics, and healthcare services, bringing together investment professionals with extensive experience in life sciences and healthcare business development.
Goldman Sachs
Goldman Sachs is a leading global investment banking, securities, and investment management firm. It provides a wide range of financial services to corporations, governments, and institutional and individual clients, including mergers and acquisitions advisory, underwriting, asset management, securities trading, and wealth management.
Clarus Ventures
Blackstone Life Sciences focuses on bringing vital medicines and technologies to market, aiming to improve patient outcomes through collaboration with pharmaceutical, biotech, and medical technology companies. The firm addresses the funding gap in the life sciences sector by investing in late-stage development of innovative products.
What's next for Sientra?
The recent major strategic investment indicates a strong vote of confidence from its backers, suggesting Sientra is poised for an expansion phase. This capital infusion is likely to be directed towards enhancing its product pipeline, expanding its market reach, and potentially exploring new applications or technologies within the medical aesthetics field. The company's trajectory, marked by consistent capital raising, points towards a strategy of sustained growth and market penetration, aiming to solidify its standing as a key player in the medical aesthetics industry.
See full Sientra company page
